360° SearchNetwork Hot Spots Trends Time Series

Domain Associates

Type: Company

Name: Domain Associates

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Cholesterol Drug Developer Esperion Therapeutics Files for IPO

Esperion Therapeutics Inc ., which was founded by the co-discover of the cholesterol medicine Lipitor, filed its registration for an initial public offering Tuesday, weeks after raising venture funding to fund clinical studies for a cholesterol-lowering ... [Published Dow Jones Financial Information Services - May 15 2013]

Entities: Esperion Therapeutics Inc, Cholesterol, IPOs, Drugs

First reported May 09 2013 - Updated May 09 2013 - 2 reports

Domain Associates, Regado Bet Big on Heart Drug

Home » Blogs » Biotech stars can rise and fall on the key decision of whether or not to “go it alone” and develop their drugs without the help of Big Pharma—it’s a risk that can either make or break a company. But Regado BioSciences, 12-year-old biot ... [Published BioPortfolio - May 09 2013]

Entities: Domain Associates, Drugs, Biotechnology

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Lipitor

Lipitor co-developer’s rebooted startup gets $33M for trials of cholesterol-lowering drug

In its second wind as a company, Esperion Therapeutics (once owned by Pfizer) has just collected $33 million to continue with clinical trials of its cholesterol-lowering drug.Plymouth, Michigan-based Esperion is in Phase II trials of ETC-1002, a once-daily ... [Published MedCity News - Apr 30 2013]

Entities: Lipitor, Drugs, Pfizer Inc, Startup, Cholesterol

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Regado gambles on $75M IPO to pay pricey PhIII tab

David J. Mazzo, president and CEO of Regado BiosciencesLate last year Regado Biosciences came up with a big $51 million round that served as a kind of down payment on a planned $120 million study of its lead therapy--an anticoagulant that adds a promising ... [Published FierceBiotech - Apr 30 2013]

Entities: IPOs, Regado Biosciences Inc, Gambling

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

PhillyInc: Their used-car start-up site is a winner

The student-led start-up ZenKars sounds as if it should have emerged from Southern California. After all, its goal is to provide used-car shoppers with a "peaceful buying experience."But ZenKars is Philadelphia-born and bred, and it won the 2013 Wharton ... [Published Philadelphia Inquirer - Apr 29 2013]

Entities: Compass Partners, Domain Associates, Mike Armstrong, Bootstrapping

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

Esperion Therapeutics Lands $33 Million In Preferred Stock Financing

ANN ARBOR - Esperion Therapeutics, which is developing new therapies to treat high cholesterol that can be taken as a pill, announced it has completed a $33 million preferred stock financing led by new investor Longitude Capital.Existing investors Aisling ... [Published Michigan Technology News - Apr 27 2013]

Entities: Esperion Therapeutics Inc, Preferred Shares, Cholesterol, Statins

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Experienced biotech team snags $33M for promising PhII cholesterol drug

Now that the successful biopharma team of Roger Newton and Tim Mayleben has reunited to run an upstart--Esperion--with a promising mid-stage cholesterol drug in the pipeline, some well-known names in the venture crowd have decided to tag along and see ... [Published FierceBiotech - Apr 25 2013]

Entities: Cholesterol, Drugs, Biotechnology

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

CTPartners Vice Chairman Ron Porter to Speak on Two Panels at California Diversity & Leadership Conference on April

NEW YORK - (BUSINESS WIRE) - Ron Porter, Vice Chairman at global executive search firm CTPartners (NYSE MKT: CTP), will speak on two leadership panels at the 4th Annual California Diversity & Leadership conference, being held April 18 - 19 at the Hilton ... [Published NewsBlaze - Apr 18 2013]

Entities: Ron Porter, CTPartners Executive Search Inc, NovaMedica, Leadership

First reported Mar 13 2013 - Updated Mar 14 2013 - 1 reports

Domain Associates Partners with Elite Consulting

U.S. venture firm Domain Associates has partnered with Elite Consulting , an advisory to the Chinese pharmaceutical and medical device industry, have partnered in a new venture called Domain Elite . The partnership will work to establish new companies ... [Published PE Hub News - Mar 13 2013]

Entities: Domain Associates, Health Care, China, Medical Devices, Life Science

First reported Mar 13 2013 - Updated Mar 13 2013 - 1 reports

The Daily Startup: Nabys Funded to Help Speed Up DNA Research

Top stories in today’s VentureWire: Art by Mike Lucas Bay City Capital, which sold DNA-sequencing startup Ion Torrent Systems for $725 million in 2010, is leading a $20 million Series D round for Nabsys as that company prepares to launch a complementary ... [Published WSJ.com: Venture Capital Dispatch - Mar 13 2013]

Entities: Startup, DNA, Ion, Clean Technology

First reported Jan 07 2013 - Updated Jan 07 2013 - 1 reports

Marinus Pharmaceuticals Adds $21M Series C

Marinus Pharmaceuticals Inc. , has added $21 million in Series C financing from Domain Associates , RusnanoMedInvest , Canaan Partners , Sofinnova Ventures and Foundation Medical Partners . Branford, Conn.-based Marinus is the developer of the ... [Published PE Hub News - Jan 07 2013]

Entities: Marinus Pharmaceuticals Inc, Ganaxolone, RUSNANO Russian Corporation of Nanotechnologies, Domain Associates

First reported Dec 19 2012 - Updated Dec 19 2012 - 1 reports

Lithera, Inc. Completes $20.6 Million Equity Financing

Easily Send & Share Press ReleasesSAN DIEGO, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced investment of $20.6 million in preferred stock equity financing. Additional investment may provide the Company with up to a total of $35.6 million ... [Published GlobeNewswire - Dec 19 2012]

Entities: Salmeterol, Amorepacific Corp, Domain Associates

Quotes

"I am very pleased to become involved with Esperion," added Patrick Enright of Longitude. "I look forward to working with Roger, Tim and the entire Esperion team to realize the full potential of ETC-1002 in patients with elevated LDL-C who cannot tolerate statin therapy."

Esperion Therapeutics completes $33M financing to advance LDL-C lowering therapy [Published Center Watch - Apr 27 2013]

"Obviously it's very early, but the drug does all the right things: lower LDL, lower triglycerides" the Cleveland Clinic's Steven Nissen tells Herper...

Experienced biotech team snags $33M for promising PhII cholesterol drug [Published FierceBiotech - Apr 25 2013]

Linda Grais, President and CEO of Ocera, stated, "The merger and concurrent financing will allow the Company to continue to advance Ocera's lead clinical programme, OCR-002, a differentiated product candidate for orphan liver diseases currently in phase 2 development. This product candidate addresses a significant unmet need in the treatment of acute hepatic encephalopathy, and we look forward to the initiation of our phase 2b trial later this year and additional phase 2a data in 2014."

Tranzyme Pharma, Ocera Therapeutics enter into merger agreement [Published PharmaBiz - Apr 25 2013]

...our patent position in the area of computer controlled injections," said Timothy J Patrick, president and chief executive officer of Carticept. "Specifically, these new patents will provide coverage for future use of the Navigator in delivering nerve blocks and other anesthesia procedures, which is currently under development. We believe our technology has the ability to improve significantly the efficiency of peripheral nerve block preparation, delivery and recordkeeping."

Carticept Medical Announces Two Additional Navigator Delivery System Patents [Published Business Wire - Apr 23 2013]

More Content

sort by: Date \| Relevance
Asmacure to Present Four Posters on Novel Pulmo... [Published FinanzNachrichten.de - May 16 2013]
Cholesterol Drug Developer Esperion Therapeutic... [Published Dow Jones Financial Information Services - May 15 2013]
ParinGenix, Inc. - Pharmaceuticals & Healthcare... [Published TransWorldNews - May 11 2013]
Tranzyme Pharma Announces First Quarter 2013 Fi... [Published Individual.com - May 09 2013]
Domain Associates, Regado Bet Big on Heart Drug [Published BioPortfolio - May 09 2013]
Domain Associates, Regado Bet Big on Heart Drug [Published Xconomy - May 09 2013]
Financing of the Fortnight Wonders If It's Time... [Published The IN VIVO Blog - May 03 2013]
East Coast Life Sciences Roundup: Aveo, Forma, ... [Published Xconomy - May 03 2013]
Lipitor co-developer’s rebooted startup gets $3... [Published MedCity News - Apr 30 2013]
Regado gambles on $75M IPO to pay pricey PhIII tab [Published FierceBiotech - Apr 30 2013]
PhillyInc: Their used-car start-up site is a wi... [Published Philadelphia Inquirer - Apr 29 2013]
Esperion Therapeutics completes $33M financing ... [Published Center Watch - Apr 27 2013]
Esperion Therapeutics Lands $33 Million In Pref... [Published Michigan Technology News - Apr 27 2013]
Experienced biotech team snags $33M for promisi... [Published FierceBiotech - Apr 25 2013]
Emerging Cholesterol Pill Could Compete With Am... [Published Forbes.com - Apr 25 2013]
Tranzyme Pharma, Ocera Therapeutics enter into ... [Published PharmaBiz - Apr 25 2013]
Esperion Therapeutics Completes $33 Million Pre... [Published Business Wire Science: Science News - Apr 25 2013]
Esperion Therapeutics Completes $33 Million Pre... [Published Business Wire Health News - Apr 25 2013]
Carticept Medical Announces Two Additional Navi... [Published Business Wire - Apr 23 2013]
Oraya Therapeutics’ INTREPID Study Published in... [Published BioMedReports - Apr 18 2013]
Oraya Therapeutics’ INTREPID Study Published in... [Published Yahoo! Finance - Apr 18 2013]
CTPartners Vice Chairman Ron Porter to Speak on... [Published NewsBlaze - Apr 18 2013]
Oraya Therapeutics' INTREPID Study Published in... [Published FinanzNachrichten.de - Apr 18 2013]
Veracyte Announces That New Study Suggests The ... [Published BioMedReports - Apr 17 2013]
Veracyte Announces That New Study Suggests The ... [Published Yahoo! Finance - Apr 17 2013]
4/15/13 - CarticeptÂ® Medical Receives 510(k) C... [Published Pharmacy Choice - Apr 15 2013]
Carticept® Medical Receives 510(k) Clearance fo... [Published Yahoo! Finance - Apr 15 2013]
Carticept® Medical Receives 510(k) Clearance fo... [Published Business Wire - Apr 15 2013]
Asmacure Dosed First Subjects With ASM-024 Dry ... [Published FinanzNachrichten.de - Apr 15 2013]
Veracyte Announces Appointment of Shelly D. Guy... [Published FinanzNachrichten.de - Apr 12 2013]

Blogs

sort by: Date \| Relevance
Financing of the Fortnight Wonders If It's Time... [Published The IN VIVO Blog - May 03 2013] Biotech workers of the world unite, you have nothing to exercise but your stock options. At least a few more do these days. We’re far from the cries of “Mayday!” that echoed from the bottom of the financial canyon four years ago, and as we write this, ...
The Daily Startup: Nabys Funded to Help Speed U... [Published WSJ.com: Venture Capital Dispatch - Mar 13 2013] Top stories in today’s VentureWire: Art by Mike Lucas Bay City Capital, which sold DNA-sequencing startup Ion Torrent Systems for $725 million in 2010, is leading a $20 million Series D round for Nabsys as that company prepares to launch a complementary ...
Financing Deal of the Year Nominee: Rusnano/Dom... [Published The IN VIVO Blog - Dec 19 2012] It's time for the IN VIVO Blog's Fifth Annual Deal of the Year! competition. This year we're once again presenting awards in three categories to highlight the most interesting and creative deal making solutions of the year. The categories are: M&A ...

Press Releases

sort by: Date \| Relevance
Esperion Therapeutics Completes $33 Million Pre... [Published Business Wire Science: Science News - Apr 25 2013]
Esperion Therapeutics Completes $33 Million Pre... [Published Business Wire Health News - Apr 25 2013]
Carticept Medical Announces Two Additional Navi... [Published Business Wire - Apr 23 2013]
Carticept® Medical Receives 510(k) Clearance fo... [Published Business Wire - Apr 15 2013]
Domain Associates and Elite Consulting Collabor... [Published PR Newswire - Mar 13 2013]